Dare Bioscience Faces Nasdaq Delisting Risk
Ticker: DARE · Form: 8-K · Filed: Feb 14, 2025 · CIK: 1401914
Sentiment: bearish
Topics: delisting, compliance, nasdaq
Related Tickers: DARE
TL;DR
Nasdaq says DARE might get delisted, they have until August to fix it.
AI Summary
On February 13, 2025, Dare Bioscience, Inc. filed an 8-K report indicating a potential delisting from the Nasdaq Capital Market. The company received a deficiency notification from Nasdaq on February 10, 2025, due to not meeting the minimum bid price requirement for continued listing. Dare Bioscience has 180 days, until August 7, 2025, to regain compliance.
Why It Matters
This filing signals potential liquidity issues and investor concern as the company must take corrective action to avoid being removed from a major stock exchange.
Risk Assessment
Risk Level: medium — The company is at risk of delisting from Nasdaq if it cannot meet the minimum bid price requirement within the specified timeframe.
Key Numbers
- 180 days — Compliance Period (Timeframe to regain minimum bid price)
Key Players & Entities
- Dare Bioscience, Inc. (company) — Registrant
- Nasdaq Capital Market (company) — Stock Exchange
- February 13, 2025 (date) — Filing Date
- February 10, 2025 (date) — Notification Date
- August 7, 2025 (date) — Compliance Deadline
FAQ
What is the primary reason for Dare Bioscience's potential delisting from Nasdaq?
Dare Bioscience received a deficiency notification from Nasdaq on February 10, 2025, because the company has not met the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
What is the exact date of the 8-K filing?
The 8-K filing was made on February 14, 2025, reporting events as of February 13, 2025.
How much time does Dare Bioscience have to regain compliance with Nasdaq's listing rules?
Dare Bioscience has 180 days from the date of the notification, which is until August 7, 2025, to regain compliance.
What specific listing rule is Dare Bioscience failing to meet?
The company is failing to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
What was the previous name of Dare Bioscience, Inc.?
Dare Bioscience, Inc. was formerly known as Cerulean Pharma Inc. and Tempo Pharmaceuticals Inc.
Filing Stats: 798 words · 3 min read · ~3 pages · Grade level 13.1 · Accepted 2025-02-14 17:10:15
Key Financial Figures
- $35.0 million — um market value of listed securities of $35.0 million (the "Minimum MVLS Rule"). The Company
Filing Documents
- form8-k.htm (8-K) — 36KB
- 0001493152-25-006958.txt ( ) — 206KB
- dare-20250213.xsd (EX-101.SCH) — 3KB
- dare-20250213_lab.xml (EX-101.LAB) — 33KB
- dare-20250213_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DAR BIOSCIENCE, INC. Dated: February 14, 2025 By: /s/ Sabrina Martucci Johnson Name: Sabrina Martucci Johnson Title: President and Chief Executive Officer -3-